E2XE34 Stock Overview An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details
Rewards Risk Analysis No risks detected for E2XE34 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Exelixis, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Exelixis Historical stock prices Current Share Price US$96.45 52 Week High US$111.44 52 Week Low US$51.22 Beta 0.53 1 Month Change -6.54% 3 Month Change -9.01% 1 Year Change 90.20% 3 Year Change 94.65% 5 Year Change n/a Change since IPO 99.17%
Recent News & Updates
Exelixis, Inc. Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Jan 26
Exelixis, Inc. Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025 Jan 25 Exelixis, Inc. to Report Q4, 2024 Results on Feb 11, 2025
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Jan 09
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024 Oct 31 See more updates
Exelixis, Inc. Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Jan 26
Exelixis, Inc. Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025 Jan 25 Exelixis, Inc. to Report Q4, 2024 Results on Feb 11, 2025
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Jan 09
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024 Oct 31 Exelixis, Inc. Revises Earnings Guidance for the Year 2024
Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 16 Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Aug 08 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.
Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors Aug 06
Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 24 Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA May 22
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024 May 01
Exelixis, Inc., Annual General Meeting, May 30, 2024 Apr 20
Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 17
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024 Feb 07
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Jan 25 Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib) Jan 24
Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares. Jan 09 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.
Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Dec 04
Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 Nov 11
Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 Oct 23
Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 19
Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Aug 25 Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Aug 04
Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 21
Exelixis, Inc. Elects Dave Johnson to its Board of Directors Jun 01
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 May 10
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors May 08 Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma Feb 15
Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors Feb 14
Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023 Feb 08
Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Jan 10
Exelixis, Inc. Provides Revenue Guidance for Full Year 2023 Jan 09 Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer Dec 23
Exelixis, Inc. Announces Board Appointments Dec 17
Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy Dec 10
Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 Dec 09
Exelixis, Inc. Provides Revenue Guidance for 2022 Nov 02
Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022 Oct 27
Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022 Sep 11
Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022 Sep 08
Exelixis, Inc. Maintains Earnings Guidance for the Fiscal Year 2022 Aug 10
Exelixis, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Exelixis, Inc. Announces COSMIC-313 Met Its Primary Endpoint Jul 12
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer Jun 22
Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients May 27
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022 May 12 Exelixis, Inc. Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Exelixis, Inc. Announces Charles Cohen to Retire from Board of Directors Apr 14
Exelixis, Inc. Provides Earnings Guidance for the Year 2022 Feb 18
Bristol Myers Squibb and Exelixis, Inc. Announces Two-Year Follow-Up Results from Analyses of the Phase 3 CheckMate -9ER Trial Feb 15
Exelixis, Inc. Provides Sales Guidance for the Year 2022 Feb 11 Shareholder Returns E2XE34 BR Biotechs BR Market 7D 0% 1.2% -0.6% 1Y 90.2% 2.5% -7.3%
See full shareholder returns
Return vs Industry: E2XE34 exceeded the BR Biotechs industry which returned 3.4% over the past year.
Return vs Market: E2XE34 exceeded the BR Market which returned -9.5% over the past year.
Price Volatility Is E2XE34's price volatile compared to industry and market? E2XE34 volatility E2XE34 Average Weekly Movement 6.5% Biotechs Industry Average Movement 9.0% Market Average Movement 5.6% 10% most volatile stocks in BR Market 9.7% 10% least volatile stocks in BR Market 3.2%
Stable Share Price: E2XE34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine E2XE34's volatility change over the past year.
About the Company Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Show more Exelixis, Inc. Fundamentals Summary How do Exelixis's earnings and revenue compare to its market cap? E2XE34 fundamental statistics Market cap R$55.63b Earnings (TTM ) R$2.71b Revenue (TTM ) R$12.09b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) E2XE34 income statement (TTM ) Revenue US$2.08b Cost of Revenue US$78.00m Gross Profit US$2.00b Other Expenses US$1.54b Earnings US$466.92m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 11, 2025
Earnings per share (EPS) 1.64 Gross Margin 96.25% Net Profit Margin 22.43% Debt/Equity Ratio 0%
How did E2XE34 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 15:50 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Exelixis, Inc. is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Peter Lawson Barclays Etzer Darout BMO Capital Markets Equity Research
Show 39 more analysts 